Lower doses venlafaxine-associated toxic hepatitis in a patient with chronic hepatitis

dc.authorid0000-0001-6203-5039
dc.authorid0000-0002-8328-3565
dc.contributor.authorŞencan, İrfan
dc.contributor.authorŞahin, İdris
dc.contributor.authorÖzçetin, Adnan
dc.date.accessioned2021-06-23T18:54:43Z
dc.date.available2021-06-23T18:54:43Z
dc.date.issued2003
dc.departmentBAİBÜ, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümüen_US
dc.description.abstractToxic hepatitis is observed with high doses of Venlafaxine. But toxic hepatitis has not been yet reported at tower doses of Venlafaxine such as 37.5 mg per day. In this case report, a case of Venlafaxine-associated toxic hepatitis with tower doses in patient with history of chronic hepatitis is presented. We suggest that liver function should be regularly monitored in patients with history of chronic hepatitis receiving Ventafaxine even at tower doses and even when their liver enzymes are normal.en_US
dc.identifier.endpage229en_US
dc.identifier.issn1682-024X
dc.identifier.issue3en_US
dc.identifier.scopus2-s2.0-0141782621en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage228en_US
dc.identifier.urihttps://hdl.handle.net/20.500.12491/4551
dc.identifier.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-0141782621&partnerID=40&md5=56287dc412fcffea225621312dce50f8
dc.identifier.volume19en_US
dc.indekslendigikaynakScopusen_US
dc.institutionauthorŞencan, İrfan
dc.institutionauthorŞahin, İdris
dc.institutionauthorÖzçetin, Adnan
dc.language.isoenen_US
dc.relation.ispartofPakistan Journal of Medical Sciencesen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectChronic Hepatitisen_US
dc.subjectToxic Hepatitisen_US
dc.subjectVentafaxineen_US
dc.titleLower doses venlafaxine-associated toxic hepatitis in a patient with chronic hepatitisen_US
dc.typeArticleen_US

Dosyalar